Grade 3 adverse events with more than 5 % incidence were fatigue ( 19 % ) , decreased neutrophils ( 14 % ) , decreased leukocytes ( 7 % ) , and decreased platelets ( 7 % ) for sunitinib and fatigue ( 10 % ) for placebo ; grade 4 adverse events were GI hemorrhage ( n = 1 ) and pancreatitis , hypocalcemia , and elevated lipase ( n = 1 ; all in same patient ) for sunitinib and thrombocytopenia ( n = 1 ) and hypernatremia ( n = 1 ) for placebo .